TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria.~* Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.~* Subject has an active psoriatic skin lesion~* Subject is naïve to etanercept and any other biologic for the treatment for PsA or psoriasis.~* Subject has no prior use of methotrexate for PsA.~* Subject has no history of tuberculosis~* Subject has a negative test for tuberculosis, hepatitis B and C.~Exclusion Criteria:~* Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.~* Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to the first dose of investigational product.~* Subject has a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to the first dose of investigational product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate Monotherapy (Type: ACTIVE_COMPARATOR): Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
- Etanercept Monotherapy (Type: EXPERIMENTAL): Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
- Methotrexate + Etanercept (Type: EXPERIMENTAL): Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Defibrotide TMA Prophylaxis Pilot Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Age 0-30 years of age~2. Life expectancy \> 6 months~3. Eastern Cooperative Oncology Group or Karnofsky Performance Status \>40~4. Meets minimum organ function requirements per institutional standard of care guiding clearance for autologous or allogeneic stem cell transplantation.~5. Patients must meet TMA High-Risk criteria 5A or 5B below:~5A. Patients undergoing tandem autologous transplant with thiotepa in one or more of the conditioning regimens~OR:~5B. . Patients with at least 3 of the following characteristics:~1. \>10 years of age~2. Non-Caucasian race/ Hispanic ethnicity~3. Undergoing haploidentical transplant~4. Minor ABO blood group mismatch~Exclusion Criteria:~1. Age \>30 years~2. Life expectancy \< 6 months~3. Known bleeding diathesis or bleeding risk deemed by the treating physician to be a contraindication to administration of anticoagulants.~4. Known hypersensitivity reaction to defibrotide~5. Any patient not meeting TMA High-Risk criteria~6. Pregnant women are excluded from this study because they will be receiving teratogenic therapy as part of the stem cell transplant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Prophylactic Defibrotide (Type: EXPERIMENTAL): 6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males between the ages of 18 and 35~* Have acute unilateral complete ACL tears with or without bucket handle medial meniscus tears that occurred within the past 6 months~* Consent to undergo an ACL reconstruction by an orthopaedic surgeon using a patellar tendon or hamstring autograft~* Will be performing supervised post-operative rehabilitation at UMHS MedSport at Dominos Farms~Exclusion Criteria:~* Patients who are undergoing a revision ACL reconstruction~* Had a previous injury to the involved knee~* Have an allergy to recombinant GH~* Have a BMI\<20 or \>35~* Have a growth disorder of bones or connective tissue, type 1 diabetes mellitus, type 2 diabetes mellitus, or who have a history of carpal tunnel syndrome, trigger finger, myopathy, cancer, endocrine disorder, hypertension or rheumatologic disorder.~* Systolic blood pressure \>140mm Hg or diastolic blood pressure \>90mm Hg, or with resting heart rate \>110 BPM or \<40 BPM at screening.~* Additionally, because GH is currently listed as a banned substance by the World Anti-Doping Agency (WADA), National Collegiate Athletics Association (NCAA) and most professional sports agencies, we will exclude patients who are current collegiate, professional or elite athletes.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Somatropin (Type: ACTIVE_COMPARATOR): Somatropin of rDNA origin
- Placebo (Type: PLACEBO_COMPARATOR): A placebo vehicle that contains somatropin diluent but no active hormone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks before first visit~* Both genders; females of child bearing potential must be willing to use appropriate contraception during the study~* Pre-bronchodilator FEV1 of at least 60% predicted~* FEV1 reversibility of at least 12% and 200mls~* Current asthma therapy that includes a non-corticosteroid controller and/or short-acting beta agonist~Exclusion Criteria:~* History of life-threatening asthma exacerbation within the past 10 years~* Asthma exacerbation requiring treatment with oral corticosteroids within the last 3 months or that required overnight hospital stay within 6 months~* Current or recent respiratory infection or current oral candida infection~* Presence of another significant respiratory disease or medical condition that is not controlled or that could affect subject safety or study outcome~* Known or suspected allergy to study drug or materials~* Taking another investigational medication or prohibited medication during the study~* Previous treatment with inhaled fluticasone furoate in a phase II or III study~* Current smokers or former smokers with significant tobacco exposure~* Children in Care

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone furoate 50mcg (Type: EXPERIMENTAL): Inhalation powder delivered by Novel Dry Powder Inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Inhalation powder delivered by Novel Dry Powder Inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* in good general health with no history of chronic illness~* normal liver function tests~* normal renal function tests~Exclusion Criteria:~* personal history of cancer except for non-melanoma skin cancer~* use of prescribed medicines~* for women, a positive pregnancy test

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebos (Type: PLACEBO_COMPARATOR): Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
- High Dose Broccoli Sprout (Type: EXPERIMENTAL): Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
- Medium Dose Broccoli Sprout (Type: EXPERIMENTAL): Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
- Low Dose Broccoli Sprout (Type: EXPERIMENTAL): Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males or females (≥ 18 years, to 75 years)~2. DSM IV TR diagnosis of schizophrenia or schizoaffective disorder (If officially instituted by study initiation: DSM V diagnoses will be used).~3. Ability to provide informed written consent~4. PANSS total score ≥ 60, positive symptom cluster, (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility and unusual thought content with at least 2 items scoring ≥ 4, or one of these items scoring ≥ 5, on a scale ranging from 1 = absent to 7 = extreme~5. Current symptom exacerbation ≥ 2 weeks, but ≤ 1 year~6. Receiving anti-psychotic medications for ≥ 4 weeks~7. For women of child bearing age, a negative pregnancy test at screening.~Exclusion Criteria:~1. Testing positive for illicit substances (marijuana or alcohol use will be assessed on a case by case basis, caffeine and nicotine are excepted)~2. Receiving pharmacological treatment for addictions (naltrexone, suboxone, acamprosate, others) will be reviewed on a case by case basis~3. Seriously unstable medical illnesses~4. Pregnant or breast feeding women~5. Known allergy or history of serious adverse event with WSE~6. Subjects who may require imminent hospitalization (examples: suicidal or aggressive behavior)~7. Currently receiving antibiotics, anti-viral, or anti-parasitic medications~8. Currently receiving immunosuppressive medications (e.g. corticosteroids, chemotherapy or transplantation or HIV/AIDs associated drugs).~9. Currently receiving NSAIDs or Aspirin (\>81 mg/day) on a daily basis or PRN use \> 2x/week (in the last 4 weeks).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sensoril® (Type: EXPERIMENTAL): Sensoril® is a proprietary extract of Withania Somnifera
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Active moderate to severe rheumatoid arthritis~* Inadequate response to \>/=3 DMARDs (non-biologic and/or biologic)~* Current treatment at stable dose for \>/=8 weeks~* Etanercept discontinued \>/=2 weeks, Anakinra \>/=1 week, Infliximab, Adalimumab, Abatacept, Golimumab, Certolizumab \>/=4 weeks, prior to baseline visit. Patients have discontinued MabThera/Rituxan or Ocrelizumab \>/=16 weeks, and must have proven B-cell repletion~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline~* Rheumatic autoimmune disease other than RA~* Functional class IV (American College of Rheumatology Classification)~* Prior history or current inflammatory joint disease other than RA~* Oral corticosteroids at a dose of \>10 mg/day prednisone equivalent~* Positive hepatitis B surface antigen (HBsAg) and / or total hepatitis B core antibodies (HBcAb) or hepatitis C virus (HCV) antibody~* Current or history of recurrent bacterial, viral, fungal or mycobaterial infection~* History of or currently active primary or secondary immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Established diagnosis of B-cell CLL by NCI Working Group criteria~* ≤1 previous line of chemotherapy~* Expected survival \>6 months~* Acceptable hematologic status, liver function, renal function, and pulmonary function~* Negative serum pregnancy test for both pre-menopausal women and for women who are \< 2 years after the onset of menopause~* Written informed consent~Exclusion Criteria:~* Prior treatment with interferon, rituximab or other monoclonal antibody~* Prior allogeneic bone marrow transplant (BMT) or autologous BMT or peripheral stem cell transplant (PBSCT) or patients who are considered to be candidates for allogeneic or autologous BMT or PSCT as assessed by their treating physician~* Fertile men or women of childbearing potential not using adequate contraception~* Severe Grade 3 or 4 non-hematological toxicity or prolonged (\> 2 weeks) Grade 3 or 4 cytopenia on prior fludarabine or nucleoside analogue regimen~* History of fludarabine-induced or clinically significant autoimmune cytopenia~* History of other malignancies within 2 years prior to study entry, except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low-grade early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent.~* Medical conditions requiring long term use (\> 1 month) of systemic corticosteroids~* Active bacterial, viral, or fungal infection requiring systemic therapy~* Severe cardiac disease~* Seizure disorders requiring anticonvulsant therapy~* Severe chronic obstructive pulmonary disease with hypoxemia~* Uncontrolled diabetes mellitus or hypertension~* Transformation to aggressive B-cell malignancy.~* Known infection with HIV, HCV, or hepatitis B~* Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study~* Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins~* Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fludarabine+Cyclophosphamide (FC) (Type: ACTIVE_COMPARATOR): None
- Fludarabine+Cyclophosphamide+Rituximab (FCR) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and older~2. Histologically confirmed (by WHO classification) untreated and relapsed indolent non-Hodgkin's B-cell lymphoma of low-grade follicular, marginal zone, lymphoplasmocytic or small lymphocytic subtypes.~3. Stage III/IV~4. Adequate bone marrow function (leukocyte count\>2,0, neutrophil count\>1.0, platelets\>50)~5. Two or more separate lymph nodes \> 1,5 cm available for biopsy or treatment.~6. Measurable disease present other than biopsy site and injection site(s).~7. Required wash-out period after previous treatment: Chemotherapy - 8 weeks, Radiotherapy - 4 weeks, Rituximab - 12 weeks~8. WHO status 0-1~9. Life expectancy of more than 6 months~10. Written informed consent~11. Able to comply with the treatment protocol -~Exclusion Criteria:~1. Patients with progressive lymphoma in need of systemic therapy or standard dose irradiation.~2. Chronic bacterial, viral or fungal infection~3. Pre-existing autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.~4. Known history of HIV~5. Central nervous system involvement of lymphoma~6. Current anticoagulant therapy which can not safely be paused during treatment injections (ASA \< 325 mg/day allowed)~7. Pregnancy -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy , rituximab and DC (Type: EXPERIMENTAL): Treatment repeated 3 times and targeting different lymph nodes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history who has had a diagnosis of psoriasis for at least 12 months and stable moderate to severe chronic plaque psoriasis~* Subject is a candidate for systemic therapy or phototherapy and has active psoriasis despite treatment with topical agents.~* Subject was able and willing to self-administer sc injections or had available qualified person(s) to administer sc injections.~* Male subjects must hve been vasectomized or practicing birth control.~Exclusion Criteria:~* Previous systemic anti-TNF therapy.~* Prior use of MTX.~* Known hypersensitivity to the constituents of adalimumab.~* Systemic therapy for psoriasis for at least 4 weeks prior to Baseline; except for biologic therapies, which must be discontinued at least 12 weeks prior to enrollment.~* Topical psoriasis therapy for at least 2 weeks prior to Baseline, except for non-corticosteroid shampoos, bland (no alpha or beta hydroxy) emollients and low potency topical corticosteroids on the palms, soles, face, inframammary area, and groin only.~* Use of tanning beds, excessive sun exposure, or phototherapy (UVB, UVA), for at least 2 weeks prior to Baseline.~* Use of PUVA for at least 4 weeks prior to Baseline.~* Use of oral or injectable corticosteroids during the study.~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study.~* Female subject who is pregnant or breast feeding or considering becoming pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known or highly suspected central nervous system (CNS) pathology referred for contrast-enhanced MRI of the CNS.~* Glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m2 derived from a serum creatinine result within four weeks prior to the first study MRI.~* Women with negative urine pregnancy test within 1 hour prior to the administration of gadoterate (the first MRI).~Exclusion Criteria:~* No enhancing lesion visible on the gadoterate-enhanced MRI scan.~* Pregnancy or breastfeeding.~* Severe cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1_Suspected CNS-lesion (Type: EXPERIMENTAL): Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
- Arm 2_Confirmed CNS-lesion (Type: EXPERIMENTAL): Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete